Oragenics Develops Automated Intranasal Device for Treating Concussed Patients

SARASOTA, Fla., June 27, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has completed a prototype of its automated intranasal device for use in concussed patients who are initially confused, dazed or unconscious in the acute phase of injury. Oragenics' lead drug candidate, ONP-002, is a new chemical entity (NCE) designed to target the brain through delivery into ...